← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksTGTXPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

TG Therapeutics, Inc. (TGTX) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$30.09
Market reference
Price Target
$49.50
+64.5% Upside
Target Range
$39.00 — $60.00
Wide divergence
Analyst Rating
Buy
13 analysts
Forward P/E19.4x
Trailing P/E200.6x
Forward PEG—
Implied Growth+317.1%
Median Target$49.50
Analyst Spread42.4%

Analysts see +64.5% upside to their consensus target of $49.50. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$30.09
Consensus$49.50
High$60.00
Low$39.00
Model$30.09
Bear Case
$39
+29.6%
Consensus
$50
+64.5%
Bull Case
$60
+99.4%
Valuation Model TargetsConfidence: 33/100
Bear$-31913
Base$30
Bull$7

Analyst Ratings Distribution

Breakdown of 13 published analyst recommendations for TGTX

11/13 analysts are bullish
+38
BearishBullish
Weighted analyst sentiment score based on 13 ratings
ConsensusBuy
Coverage13 Analysts
Net Score+38
Bull / Bear85% / 8%
Strong Buy00%
Buy1185%
Hold18%
Sell18%
Strong Sell00%
Strong Buy
00%
Buy
1185%
Hold
18%
Sell
18%
Strong Sell
00%
Recommendation Mix85% Buy · 8% Hold · 8% Sell
Buy (11)Hold (1)Sell (1)

TGTX Price Target Analysis

Updated February 28, 2026

As of February 28, 2026, TG Therapeutics, Inc. (TGTX) has a Wall Street consensus price target of $49.50, based on estimates from 13 covering analysts. With the stock currently trading at $30.09, this represents a potential upside of +64.5%. The company has a market capitalization of $4.75B.

Analyst price targets range from a low of $39.00 to a high of $60.00, representing a 42% spread in expectations. The median target of $49.50 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, TGTX trades at a trailing P/E of 200.6x and forward P/E of 19.4x. Analysts expect EPS to grow +317.1% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $30.09, with bear and bull scenarios of $-31912.72 and $6.68 respectively. Model confidence stands at 33/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+1290.7%
Avg Forward P/E23.5x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
TGTXTG Therapeutics, Inc.
$4.8B$30.09$49.50+64.5%Buy19.4x13
ARGXargenx SE$47.5B$766.92$1026.71+33.9%Buy25.6x35
CANFCan-Fite BioPharma Ltd.$14.2B$4.75$7.25+52.6%Buy—4
AKTXAkari Therapeutics, Plc$12.6B$0.24$30.00+12601.1%Buy—7
ABVXAbivax S.A.$9.6B$121.28$142.50+17.5%Buy—8
RAPTRAPT Therapeutics, Inc.$7.7B$57.98$60.00+3.5%Hold—15
KYMRKymera Therapeutics, Inc.$7.4B$91.35$117.31+28.4%Buy—26
PTGXProtagonist Therapeutics, Inc.$5.8B$92.08$111.75+21.4%Buy25.4x24
IMVTImmunovant, Inc.$5.6B$27.73$35.67+28.6%Buy—23
APGEApogee Therapeutics, Inc.$4.2B$70.00$108.86+55.5%Buy—7

Upside Potential Comparison

AKTX
+12601.1%
TGTX
+64.5%
APGE
+55.5%
CANF
+52.6%
ARGX
+33.9%
IMVT
+28.6%
KYMR
+28.4%
PTGX
+21.4%

See TGTX's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is TGTX Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare TGTX vs AGIO

See how TGTX stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the TGTX stock price target for 2026?

The consensus Wall Street price target for TGTX is $49.5, representing 64.5% upside from the current price of $30.09. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is TGTX a buy, sell, or hold?

TGTX has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $49.5 implies 64.5% upside from current levels.

Is TGTX stock overvalued or undervalued?

With a forward P/E of 19.3966x, TGTX trades at a relatively low valuation. The consensus target of $49.5 implies 64.5% appreciation, suggesting meaningful undervaluation.

How high can TGTX stock go?

The most bullish Wall Street analyst has a price target of $60 for TGTX, while the most conservative target is $39. The consensus of $49.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $7 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover TGTX stock?

TGTX is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the TGTX stock forecast?

The 12-month TGTX stock forecast based on 13 Wall Street analysts shows a consensus price target of $49.5, with estimates ranging from $39 (bear case) to $60 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $30, with bear/bull scenarios of $-31913/$7.

What is TGTX's fair value based on fundamentals?

Our quantitative valuation model calculates TGTX's fair value at $30 (base case), with a bear case of $-31913 and bull case of $7. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 33/100.

What is TGTX's forward P/E ratio?

TGTX trades at a forward P/E ratio of 19.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 200.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy TGTX stock?

Wall Street analysts are very optimistic on TGTX, with a "Buy" consensus rating and $49.5 price target (64.5% upside). 11 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do TGTX price targets vary so much?

TGTX analyst price targets range from $39 to $60, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $49.5 consensus represents the middle ground. Our model's $-31913-$7 range provides an independent fundamental perspective.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.